Published Aug 12, 2026
Aktis Oncology Q1 FY2026: The Post-IPO Runway Bet on Nectin-4 and Actinium
In-depth research on AKTS covering the business overview, key financial moves, risk frame, and the bottom-line on what changed since the last report.
3,185 words14 min read
Read report